1. Home
  2. PHGE vs STI Comparison

PHGE vs STI Comparison

Compare PHGE & STI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • STI
  • Stock Information
  • Founded
  • PHGE 2015
  • STI 2014
  • Country
  • PHGE Israel
  • STI United States
  • Employees
  • PHGE N/A
  • STI N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • STI
  • Sector
  • PHGE Health Care
  • STI
  • Exchange
  • PHGE Nasdaq
  • STI NYSE
  • Market Cap
  • PHGE 14.6M
  • STI 15.4M
  • IPO Year
  • PHGE N/A
  • STI N/A
  • Fundamental
  • Price
  • PHGE $0.50
  • STI $3.30
  • Analyst Decision
  • PHGE Strong Buy
  • STI
  • Analyst Count
  • PHGE 2
  • STI 0
  • Target Price
  • PHGE $20.00
  • STI N/A
  • AVG Volume (30 Days)
  • PHGE 85.8K
  • STI 559.3K
  • Earning Date
  • PHGE 05-15-2025
  • STI 05-15-2025
  • Dividend Yield
  • PHGE N/A
  • STI N/A
  • EPS Growth
  • PHGE N/A
  • STI N/A
  • EPS
  • PHGE N/A
  • STI 6.72
  • Revenue
  • PHGE N/A
  • STI N/A
  • Revenue This Year
  • PHGE N/A
  • STI N/A
  • Revenue Next Year
  • PHGE N/A
  • STI N/A
  • P/E Ratio
  • PHGE N/A
  • STI $0.49
  • Revenue Growth
  • PHGE N/A
  • STI N/A
  • 52 Week Low
  • PHGE $0.45
  • STI $2.94
  • 52 Week High
  • PHGE $4.90
  • STI $110.50
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 40.96
  • STI 41.83
  • Support Level
  • PHGE $0.45
  • STI $3.18
  • Resistance Level
  • PHGE $0.52
  • STI $3.72
  • Average True Range (ATR)
  • PHGE 0.04
  • STI 0.33
  • MACD
  • PHGE -0.00
  • STI 0.08
  • Stochastic Oscillator
  • PHGE 39.31
  • STI 45.56

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

About STI SOLIDION TECHNOLOGY INC

Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a IP leader in both the high-capacity anode and the high-energy solid-state battery.

Share on Social Networks: